Navigation Links
Argos Confirms Improved RNA Amplification Protocol Enhances Quality of Antigen-Specific Immune Response

DURHAM, N.C., May 8, 2013 /PRNewswire/ -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced the publication of key findings on its proprietary RNA amplification process. The study confirms the Company's improved RNA amplification techniques enhance the quality of the resultant antigen-specific immune response.

The study, which was published in the May issue of Molecular Therapy-Nucleic Acids, a companion journal to Molecular Therapy, evaluated the properties of renal cell carcinoma RNA after amplification and following introduction into dendritic cells using newly developed tests. Investigators found that the improved amplification process resulted in superior protein expression levels and a greater capacity of dendritic cells to induce a strong T-cell response.

"The new RNA amplification techniques we have developed further validate Argos Therapeutics' leadership in the field of RNA-containing therapeutics," said Charles Nicolette , Ph.D., Chief Scientific Officer and Vice President of Research and Development of Argos Therapeutics. "With the ADAPT Phase 3 study for AGS-003 well underway, the improved amplification process should help to provoke stronger immune responses in study patients and ultimately lead to positive clinical outcomes."

By tracking specific antigens, researchers were able to demonstrate that the protein antigens were produced inside dendritic cells transfected with the amplified RNA. It was further shown that RNA amplified using the improved process resulted not only in higher levels of antigen expression but also in greater numbers of antigen-specific memory T cell responses. In a completed Phase 2 study with AGS-003, this specific type of immune response was shown to correlate with good clinical outcomes, including improved overall survival.

The improved RNA amplification process is being used in Argos Therapeutics' ADAPT Phase 3 clinical study for AGS-003, the company's most advanced product candidate. To create AGS-003, RNA is isolated from a small tumor sample obtained from standard tumor removal surgery (nephrectomy), and dendritic cells are taken during a single leukapheresis procedure. The tumor RNA is used to "program" the dendritic cells with the entire disease-antigen repertoire to trigger an immune response against the patient's specific cancer. These antigen-loaded dendritic cells are formulated into a ready-to-use, intradermal injection.

For more information about AGS-003 and the ADAPT study, visit

About the Arcelis™ Technology Platform

Arcelis is a fully personalized, active immunotherapy technology that captures all antigens, including mutated and variant antigens that are specific to each patient's disease. It has been shown to overcome immunosuppression by producing a durable memory T-cell response without adjuvants that are associated with toxicity. The technology can be leveraged to manufacture personalized therapies for any cancer or infectious disease.

The Arcelis process integrates readily into many current treatment paradigms, using only a small tumor or blood sample and the patient's own dendritic cells, which are derived and optimized following a single leukapheresis procedure. The proprietary process uses RNA isolated from the patient sample to program the dendritic cells to target the entire disease-antigen repertoire. The activated, antigen-loaded dendritic cells are then formulated into the patient's plasma and administered as an intradermal injection to produce the desired patient-specific immune response.

Arcelis technology also overcomes many of the manufacturing and commercialization challenges that have impeded other personalized cancer immunotherapies. Automated processes allow a single facility to serve all of North America and can be used to treat any cancer or infectious disease with the same manufacturing process and equipment.

About Argos Therapeutics

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform. Argos´ most advanced product candidate AGS-003 has initiated a Phase 3 study for the treatment of mRCC, and the Company plans to have data from its Phase 2b study of AGS-004 for the treatment of HIV in late 2013. For more information about Argos Therapeutics, visit


The Ruth Group
Caitlin Cox (media) 
(646) 536-7033

Nicole Greenbaum (investors) 
(646) 536-7009

Argos Therapeutics
Jeff Abbey (partners) 
(919) 287-6308


SOURCE Argos Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
2. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
3. Collegium Announces Results of Chronic Pain Patient Survey - Confirms Significant Unmet Medical Need for a Differentiated, Abuse-Deterrent, Extended-Release Opioid
4. New CDC Study Confirms Effectiveness of UV-C Disinfection in Reducing Harmful Pathogens for Hospitals
5. Lilly Confirms Date and Conference Call for First-Quarter 2013 Financial Results Announcement
6. Perrigo Confirms First to File Patent Challenge for Generic Version of Testosterone Gel 1.62%
7. Perrigo Confirms FDA Approval For Testosterone Gel 1%
8. New Analysis Confirms Albumin Preserves Kidney Function and Improves Survival in Common Abdominal Infection of Liver Disease
9. Beth Israel Deaconess Medical Center, Harvard Medical School Study Confirms Cannabis Sciences Approach to Development of CS-TATI-1 to Inhibit Kaposi Sarcoma
10. Quest Diagnostics Confirms Investor Day on November 16
11. TUV Rheinland Confirms Apparent Fraud in Mislabeling of DRX Products Manufactured by HTRD and Excite Medical
Post Your Comments:
(Date:11/25/2015)... 2015 Kitov Pharma ceuticals ... a biopharmaceutical company focused on the development of therapeutic ... today announced the closing of its previously announced underwritten ... ), each representing 20 ordinary shares of the Company, ... ADSs and warrants were issued in a fixed combination ...
(Date:11/25/2015)...  Today AVACEN Medical announced the issue of United States patent No. ... ". This patent shields the company,s AVACEN 100 dry heat therapy medical device and specific methods ... Photo - ... ... ...
(Date:11/25/2015)... , Nov. 25, 2015 USP 800 ... drug preparations (e.g. pharmacists, pharmacy technicians, nurses, physicians, ... technicians). The chapter also covers all entities which ... pharmacies, hospitals, other healthcare institutions, patient treatment clinics, ... --> --> What is ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert ... Organizations, One Beat ” campaign. The partnership between the two groups began in 2014 ... MAP International’s cause. , MAP International was founded in 1954 and is an international ...
(Date:11/25/2015)... ... ... On November 25, 2015, officials of Narconon Arrowhead , the drug rehabilitation ... new cutting edge recovery program that has been 50 years in the making. ... with the purpose to free addicts from the symptoms and negative behaviors of addiction. ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of Botox® for ... aware of the benefits of Botox® in the treatment of moderate facial wrinkling, few ... and pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, and Bruxism ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical Study conducted by an ... IL, UV Angel is evaluating the efficacy of its product and its disinfection protocol. ... 30 beds) from May 2014 through October 2015 at a 360-bed, acute-care, academic medical ...
(Date:11/25/2015)... Spring, Md (PRWEB) , ... November 25, 2015 ... ... Pulmonary Hypertension Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible ... history of this disease. The Periwinkle Pioneers, nominated by the public, will receive ...
Breaking Medicine News(10 mins):